Discover how Quanticate supported the sponsor by consolidating and analysing safety data across multiple trials, spanning early and later development phases, into an ISS designed to inform monitoring strategy and dose considerations.
Discover how Quanticate delivered tailored statistical programming support for a real-world evidence outcomes research analysis in a rare disease study.
Discover how Quanticate supported an adaptive Phase 2 oncology study with integrated data management and statistical programming for PK/PD, safety, biomarker tracking, and dose decision-making in advanced prostate cancer.
See how Quanticate supported a decentralised Phase 3 clinical study with tailored data management, real-time oversight, and high-quality longitudinal data for regulatory use.
Discover how Quanticate supported adaptive dose-finding with clean data, consistent reporting, and timely decision support for a complex Phase 1 study.
Discover how Quanticate supported a complex early-phase study with expert clinical data management, biostatistics, and faster regulatory-ready data delivery.
A Case Study exploring the impact of safety Monitoring Committees and extended consultation support for a dose-finding Phase I Oncology Clinical Trial.
One of the most powerful aspects for ensuring a successful relationship, and a key part of the FSP model, is the governance between the sponsor and CRO
This case study presents a long-term Functional Service Provision with one of the top five pharmaceutical company across our biostatistics and clinical programming services.
Quanticate has been working successfully with a large Scandinavian pharmaceutical company over the past 12 months in the area of clinical data management (CDM) and is focused on the delivery of clean quality clinical trial databases.